A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Running, not enrolling · Phase 3
Conditions studied: Advanced Upper Gastrointestinal Tract Adenocarcinoma
In brief
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Key facts
- Study ID
- NCT05568095
- Run by
- Arcus Biosciences, Inc.
- People needed
- 1040
- Starts
- 2022-11-21
- Expected to finish
- 2026-08-01
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Zhengzhou, China
- Research Site — Bordeaux, France
- Research Site — Brest, France
- Research Site — Caen, France
- Research Site — Lille, France
- Research Site — Lyon, France
- Research Site — Montpellier, France
- Research Site — Plérin, France
- Research Site — Poitiers, France
- Research Site — Toulouse, France
- Research Site — Villejuif, France
- Research Site — Kutaisi, Georgia
- Research Site — Tbilisi, Georgia
- Research Site — Tbilisi, Georgia
- Research Site — Tbilisi, Georgia
- Research Site — Tbilisi, Georgia
- Research Site — Guatemala City, Guatemala
- Research Site — Quetzaltenango, Guatemala
- Research Site — Happy Valley, Hong Kong
- Research Site — Hong Kong, Hong Kong
- Research Site — Tuenmen, Hong Kong
- Research Site — Budapest, Hungary
- Research Site — Kecskemét, Hungary
- Research Site — Pécs, Hungary
- Research Site — Tianjin, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.